• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.82% Nasdaq Up0.41%

    More On SKP.L



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Skyepharma PLC (SKP.L)

    339.00 Down 0.75(0.22%) 11:35AM EDT
    ProfileGet Profile for:
    Skyepharma PLC
    46-48 Grosvenor Gardens
    London, SW1W 0EB
    United Kingdom - Map
    Phone: 44 20 7881 0524
    Fax: 44 20 7881 1199
    Website: http://www.skyepharma.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:92

    Business Summary 

    Skyepharma PLC develops and sells oral and inhalation pharmaceutical products. The company’s inhalation products include flutiform, a multi-dose pressurized metered dose inhaler for the treatment of bronchial asthma; Anoro Ellipta and Incruse Ellipta multi-dose dry powder inhalers for the treatment of chronic obstructive pulmonary disease (COPD); and Relvar Ellipta/Breo Ellipta multi-dose dry powder inhaler for the treatment of asthma and COPD. It also offers Solaraze, a topical gel treatment for actinic keratosis; and Exparel, a bupivacaine injectable product for post-surgical pain management. The company’s oral drug delivery products comprise Paxil CR, an anti-depressant; Sular, a calcium channel blocker antihypertensive agent; Xatral OD, a selective alpha blocker for the treatment of BPH (urinary symptoms); Requip for Parkinson’s disease; Diclofenacratiopharm uno, a dual release diclofenac sodium formulation for pain/inflammation; and ZYFLO CR, an extended-release formulation of the oral asthma drug zileuton. Its oral drug delivery products also comprise Madopar DR, an oral treatment for Parkinson’s disease; Lodotra, a night-time release formulation of low dose prednisone for the treatment of morning stiffness associated with rheumatoid arthritis; Triglide, an oral treatment for elevated blood lipid disorders; and Coruno for the oral treatment of chronic angina pectoris. The company has partnerships with various companies, including GlaxoSmithKline, Sanofi, Mundipharma, and Kyorin worldwide. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.

    Key Statistics

    Company Websites 
    Home Page
    Investor Relations
    Search Yahoo! for:
    More on Skyepharma PLC

    Key Executives 
    Mr. Peter William Grant , 59
    Chief Exec. Officer and Exec. Director
    Mr. Andrew Derodra , 49
    Chief Financial Officer and Exec. Director
    Mr. John Murphy , 62
    Gen. Counsel and Company Sec.
    Mr. Christian Pangratz ,
    Exec. VP of Bus. Devel. and Alliance Management
    Dr. Geraldine Venthoye ,
    Exec. VP of Pharmaceutical Devel.
    Dr. Guy Vergnault ,
    Exec. VP of Oral Drug Delivery Solutions
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in GBp.